Vernakalant is a mixed sodium/potassium channel blocker with selective action on atrial ion channels, used for the acute pharmacological cardioversion of recent-onset atrial fibrillation; it is clinically indicated for the treatment of atrial fibrillation and has demonstrated superior efficacy compared to amiodarone in restoring sinus rhythm.